Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 50Neoplasm Metastasis 13Breast Neoplasms 9Carcinoma, Renal Cell 6Pain 5Osteoporosis 5Neoplasms 3Multiple Myeloma 3Kidney Neoplasms 3Lung Neoplasms 2Bone Neoplasms 2Bone Diseases, Metabolic 2Urologic Neoplasms 1Renal Insufficiency 1Insulin Resistance 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Non-Small-Cell Lung 1Bone Diseases 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Zoledronic Acid × Genitourinary × Clear all
NCT00226954 2020-03-18

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Stanford University

Phase 2 Terminated
23 enrolled
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡